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PERSPECTIVE
A framework for interpreting genome-wide association
studies of psychiatric disorders
The Psychiatric GWAS Consortium Steering Committee
Genome-wide association studies (GWAS) have yielded a plethora of new findings in the past 3
years. By early 2009, GWAS on 47 samples of subjects with attention-deficit hyperactivity
disorder, autism, bipolar disorder, major depressive disorder and schizophrenia will be
completed. Taken together, these GWAS constitute the largest biological experiment ever
conducted in psychiatry (59 000 independent cases and controls, 7700 family trios and > 40
billion genotypes). We know that GWAS can work, and the question now is whether it will work
for psychiatric disorders. In this review, we describe these studies, the Psychiatric GWAS
Consortium for meta-analyses of these data, and provide a logical framework for interpretation
of some of the conceivable outcomes.
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Genome-wide association studies (GWAS) have
yielded confirmed associations for complex diseases
in almost all medical specialties. Since 2005, there
have been genetic breakthroughs in cardiology,
endocrinology, gastroenterology, hepatology, infec-
tious disease, oncology, ophthalmology, neurology,
pulmonology and rheumatology. The success of
GWAS for nonpsychiatric complex diseases has been
exceptional – as of 1 August 2008, there were 197
associations where the initial GWAS finding repli-
cated in one or more additional samples with a
P-value < 510–8 (a defensible choice for genome-
wide significance).1 Recent papers describing signifi-
cant and replicated associations for autism,2 bipolar
disorder3 and schizophrenia4–6 suggest that psychiatry
has joined this list. By the end of 2008, GWAS on 42
samples of subjects of European ancestry with atten-
tion-deficit hyperactivity disorder (ADHD), autism,
bipolar disorder, major depressive disorder and schizo-
phrenia will have been completed. Taken together, these
GWAS constitute the largest biological experiment ever
conducted in psychiatry: > 59 000 independent cases
and controls, > 7700 family trios, on the order of
500 000 single nucleotide polymorphism (SNP) geno-
types per subject, and a total of > 40 billion genotypes.
The purpose of this article is to consider the ‘big
picture’ and to provide a logical framework for the
possible outcomes of these studies. This is not a
review of GWAS per se as many excellent reviews of
this technically and statistically intricate methodo-
logical approach are available.7–12 This is also not a
review of the advantages and disadvantages of
different study designs and sampling strategies for
the dissection of complex psychiatric traits. We
would like to consider how the dozens of GWAS
papers that will soon be in the literature can be
synthesized: what can integrated mega-analyses
(meta-analysis is based on summary data (for exam-
ple, odds ratios) from all available studies whereas
‘mega-analysis’ uses individual-level genotype and
phenotype data) of all available GWAS data tell us
about the etiology of these psychiatric disorders? This
is an exceptional opportunity as positive or negative
results will enable us to learn hard facts about these
critically important psychiatric disorders. We suggest
that it is not a matter of ‘success versus failure’ or
‘optimism versus pessimism’ but rather an opportu-
nity for systematic and logical approaches to empiri-
cal data whereby both positive and appropriately
qualified negative findings are informative.
The Psychiatric GWAS Consortium
The studies that comprise the Psychiatric GWAS
Consortium (PGC; http://pgc.unc.edu) are shown in
Table 1. GWAS data for ADHD, autism, bipolar
disorder, major depressive disorder and schizophre-
nia from 42 samples of European subjects should be
available for mega-analyses by early 2009 ( > 59 000
independent cases and controls and > 7700 family
trios). To our knowledge, the PGC will have access to
the largest set of GWAS data available.
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A major change in human genetics in the past 5 years
has been in the growth of controlled-access data
repositories, and individual phenotype and genotype
data are now available for many of the studies in Table
1. When the PGC mega-analyses are completed, most
data will be available to researchers via the NIMH
Human Genetics Initiative (http://nimhgenetics.org).
Although the ready availability of GWAS data is a
benefit to the field by allowing rapid application of a
wide range of analytic strategies to GWAS data, there
are potential disadvantages. GWAS mega-analysis is
complex and requires considerable care and expertise
to be done validly. For psychiatric phenotypes, there
is the additional challenge of working with disease
entities based largely on clinical description, with
unknown biological validity and having both sub-
stantial clinical variation within diagnostic categories
as well as overlaps across categories.13 Given the
urgent need to know if there are replicable genotype–
phenotype associations, a new type of collaboration
was required.
The purpose of the PGC is to conduct rigorous and
comprehensive within- and cross-disorder GWAS
mega-analyses. The PGC began in early 2007 with
the principal investigators of the four GAIN GWAS,14
and within six months had grown to 110 participating
scientists from 54 institutions in 11 countries. The
PGC has a coordinating committee, five disease-
working groups, a cross-disorder group, a statistical
analysis and computational group, and a cluster
computer for statistical analysis. It is remarkable that
almost all investigators approached agreed to partici-
pate and that no one has left the PGC. Most effort is
donated but we have obtained funding from the
NIMH, the Netherlands Scientific Organization, Her-
senstichting Nederland and NARSAD.
The PGC has two major specific aims. (1) Within-
disorder mega-analyses: conduct separate mega-ana-
lyses of all available GWAS data for ADHD, autism,
bipolar disorder, major depressive disorder, and
schizophrenia to attempt to identify genetic variation
convincingly associated with any one of these five
disorders. (2) Cross-disorder mega-analyses: the clini-
cally-derived DSM-IV and ICD-10 definitions may not
directly reflect the fundamental genetic architec-
ture.15 There are two subaims. (2a) Conduct mega-
analysis to identify genetic variation convincingly
associated with conventional definitions of two or
more disorders. This nosological aim could assist in
delineating the boundaries of this set of disorders.
(2b) An expert working group will convert epidemio-
logical and genetic epidemiological evidence into
explicit hypotheses about overlap among these dis-
orders, and then conduct mega-analyses based on
these definitions (for example, to examine the lifetime
presence of idiopathic psychotic features without
regard to diagnostic context).
We anticipate that interim mega-analyses for Aims
1 and 2a will be completed by late 2008 and final
mega-analyses by mid-2009. Updated results will be
posted on the PGC web site (http://pgc.unc.edu). The
standard of evidence applied will be strict and
conform to that recommended in human genetics.9
Statistical power should be superior to any earlier
study in psychiatric genetics. As a rough illustration,
the minimum detectable genotypic relative risk for
Aim 1 is 1.161 (assuming 10 000 cases for one
disorder, 10 000 controls, a= 1 10–8,1 minor allele
frequency = 0.25, and log-additive model). For the
nosological Aim 2a, the minimum detectable geno-
typic relative risk is 1.100 (same assumptions but
with 25 000 cases and 25 000 controls). Effect sizes
from the literature for other complex traits are usually
larger than these minima.16
A framework for interpreting GWAS of psychiatric
disorders
Approach
We emphasize that the framework presented here is
not the only possible formulation. Indeed, the recent
history of human genetics has been full of unantici-
pated empirical results and it is quite possible that
the future will eventuate differently from the frame-
work presented below. At the same time, we believe it
important that we think about these studies in an
integrated and systematic manner.
The goal of the PGC is to identify convincing
genetic variation-disease associations. A convincing
association would be extremely unlikely to result
Table 1 Summary of GWAS samples expected by the end of 2008
Disorder Samples Casesa Controlsb Trios
ADHD 6 1418 0 2443
Autism 6 652 6000 4661
Bipolar disorder 10 7075 10 559 0
Major depressive disorder 9 12 926 9618 0
Schizophrenia 11 9588 13 500 650
Totalc 42 31 659 26 945 7772
Abbreviation: ADHD, attention-deficit hyperactivity disorder.
aAll cases are independent.
bControls within each disorder are independent.
cColumn totals excludes duplicates and are not necessarily a simple sum of the rows.
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from chance, show consistent effect sizes across all or
almost all samples and be impervious to vigorous
attempts to disprove the finding (for example, by
investigating sources of bias, confirmatory genotyp-
ing, and so on). Careful attention will be paid to the
impact of potential sources of heterogeneity17 with
the goal of assessing its impact without minimizing
its presence.
Biological plausibility is not an initial requirement
for a convincing statistical association, as there are
many examples in human genetics of previously
unsuspected candidate genes nonetheless showing
highly compelling associations. For example, multi-
ple SNPs in intron 1 of the FTO gene were associated
with body mass index in 13 cohorts with 38 759
participants18 and yet ‘FTO’ does not appear in an
exhaustive 116 page compilation of genetic studies of
obesity.19 Some strong associations are in gene
deserts: multiple studies have found convincing
association between prostate cancer and a region on
8q24 that is B250 kb from the nearest annotated
gene.20 Both of these examples are being intensively
investigated and we suspect that a compelling
mechanistic ‘story’ will emerge in the near future.
The presence of a compelling association without an
obvious biological mechanism establishes a priority
research area for molecular biology and neuroscience
of a psychiatric disorder.
The PGC will use mega-analysis as the main
analytic tool as individual-level data will be available
from almost all samples. To wield this tool appro-
priately, a number of preconditions must be met.
First, genotype data from different GWAS platforms
must be made comparable as the direct overlap
between platforms is often modest. This requires
meticulous quality control for the inclusion of both
SNPs and subjects and attention to the factors that can
cause bias (for example, population stratification,
cryptic relatedness or genotyping batch effects).
Genotype harmonization can be accomplished using
imputation (21,22, for example) so that the same set of
B2 million23,24 directly or imputed SNP genotypes
are available for all subjects. Second, phenotypes
need to be harmonized across studies. This is one of
the most crucial components of the PGC and we are
fortunate to have world experts directing the work.
Third, the mega-analyses will assess potential hetero-
geneity of associations across samples.
An interpretive framework
A decision-tree schematic of the potential outcomes
of the PGC mega-analyses is shown in Figure 1. Note
that many of the possibilities in Figure 1 are not
mutually exclusive and different disorders may take
different paths through this framework. It is possible
that there eventually will be dozens or hundreds of
sequence variants strictly associated with these
disorders with frequencies ranging from very rare to
common.
Figure 1 Flowchart of a conceivable set of outcomes for the planned Psychiatric GWAS Consortium (PGC) mega-analyses
for five critically important psychiatric disorders. See text for explanations. Abbreviations: GWAS, genome-wide association
study; MA, mega-analysis; GxE, gene–environment interaction; CNS, central nervous system; GxG, gene–gene interaction or
epistasis;, N, sample size; GRR, genetic relative risk.
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Possibility ‘a’. GWAS mega-analysis for the within-
disorder Aim 1 (that is, conventional definitions of
ADHD, autism, bipolar disorder, major depressive
disorder and schizophrenia) identifies one or more
compelling associations with an SNP, haplotype or
copy number variant. This is the most fortuitous
outcome and a ‘Holy Grail’ of psychiatric genetics.
This would constitute a historical advance if any
such regions were identified. It is difficult to
overemphasize how important such a landmark
would be to patients, families, clinicians and
researchers. In this instance, a wealth of studies
become possible including identifying environmental
main effects and gene–environment interaction,
mechanistic studies of how genetic variation might
lead to a clinical outcome, brain imaging studies of
cases with and without the genetic variant,
investigation of the variant in unaffected population
samples and in different case groups, and so on.
Autism,2 bipolar disorder3 and schizophrenia4–6 now
each have likely examples of possibility ‘a’.
Bottom-line. What is the utility of a possibility ‘a’
finding? The immediate implications are described
above. On an intermediate scale, such an association
gives biologists and neuroscientists an excellent
starting point for attempting to determine how
genetic variation in an associated region (along with
nearby genes or related pathways) changes
vulnerability to these psychiatric disorders. For
clinical researchers, such associations could provide
a useful way to stratify clinical samples to investigate
relationships with clinically relevant phenomena (for
example, brain structure/function or treatment
outcome). For epidemiologists, the study of how
environmental factors could interact with such an
association to alter disease risk is of definite
importance. The long-term goals of this research are
to develop a comprehensive understanding of how
genetic and environmental factors act and interact
over development to produce these disorders. Such
knowledge could then be used in a public health
context rationally to prevent disease, to identify cases
earlier to initiate treatment, and to minimize
morbidity and mortality and to derive more
efficacious treatments.
Possibility ‘b’. If the Aim 1 mega-analyses do not
identify any compelling associations, the analytic
plans for each disorder-working group specify several
ways to identify putatively more homogeneous
subgroups (for example, recurrent, early-onset major
depressive disorder or schizophrenia with prominent
negative symptoms). It is conceivable that these
secondary analyses could identify compelling
associations (after appropriate correction for
multiple testing).
Possibility ‘c’. Aim 2 cross-disorder mega-analyses.
From the perspective of the genetic architecture of
these five disorders, it is possible that our clinically
derived nomenclature (DSM-IV or ICD-10) has
imposed divisions between disorders where, from a
genetic perspective, similarities outweigh differences.
In this instance, Aim 2 mega-analyses using
conventional or expert-refined definitions of illness
or subphenotypes might detect compelling
associations that transcend traditional diagnostic
boundaries.
Possibility ‘d’. The statistical model for the
relationship between genetic variation and a
psychiatric phenotype used in the mega-analyses is
perhaps the simplest conceivable model: genetic
variation acts in an additive manner to increase the
probability of a disorder. This additive model has
worked exceptionally well in human genetics as it is
relatively robust to misspecification of the true model.
In other words, if the true model is dominant, if the
genotyped SNP is in linkage disequilibrium with a
causal variant, or if the true model involves a gene–
gene or gene–environment interaction, an additive
model can detect the signal even if the true model is
not explicitly specified. However, it is possible to
imagine scenarios where interactions have no
detectable additive main effect (for example, a
genetic effect increases risk in the presence of an
environmental risk factor to which half the
population is exposed and decreases risk by the
same amount in its absence). In this instance,
explicitly modeling the interaction or the use of
nontraditional data mining methods could help.
Possibility ‘e’. It is possible that the minimum
detectible genetic relative risks afforded by the
currently available sample sizes are too small. This
could be because effect sizes are smaller for
psychiatric disorders or due to etiological
heterogeneity or diagnostic imprecision leading to
dilution of the genetic relative risk. In this instance,
increasing the available sample sizes with GWAS
genotyping would be important. Collection of
considerably larger numbers of cases for the major
psychiatric disorders is ongoing in the United States
and Europe and could resolve this issue on the 1–3
year horizon.
The ‘f’’ Possibility. The box labeled ‘f’’ in Figure 1
represents the most bedeviling and yet the most
intriguing possibility in the framework. The
likelihood of option ‘f’’ is the outcome about which
GWAS pundits debate with variable degrees of
optimism and pessimism. In our view, we cannot
know whether we have reached option ‘f’’ until we
have carefully worked through a flowchart like that in
Figure 1 which could take 2–4 years. For the sake of
argument, assume that option ‘f’ becomes tenable for
one or more of ADHD, autism, bipolar disorder, major
depressive disorder and schizophrenia. What does
this tell us about the fundamental nature of a
disorder?
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First, we learn what these disorders are not. GWAS
is predicated upon a number of assumptions: if one or
more does not hold, option ‘f’ could occur. It is
disappointing to learn what a disorder is not (as
opposed to the positive identification of a compelling
association), but such knowledge is crucial so that the
next generation of research studies can be appro-
priately focused. Indeed, this sort of iterative process
describes the history of psychiatric genetics to date
which has been one of such exclusions. For example,
43 years ago it was assumed that schizophrenia was
caused by a single dominant gene with 25% pene-
trance25—results from 31 genome-wide linkage stu-
dies26 have shown that there is no common effect of
this magnitude and subsequent study designs have
taken this datum into account. Knowledge, for
example, that there is no single locus conferring a
genetic relative risk of more than 1.075 under a set of
assumptions (genetic model, allele frequency and
heterogeneity) for a disorder will assist in figuring out
what to do next. As another example, learning that
there are no loci (under a set of assumptions) that
confer risk for bipolar disorder-schizophrenia, major
depressive-bipolar disorder or ADHD-bipolar disorder
will provide important evidence in regard to nosologi-
cal debates about these disorders. Thus, even if we do
not gain the positive knowledge of a compelling genetic
association, option ‘f’ enables us to learn.
Second, assumptions about the fundamental genet-
ic architecture of these disorders may be incorrect.
The most crucial aspects of the genetic architecture
are the number of genomic regions involved and, for
each locus, the genetic model by which it impacts
phenotypic risk and its relative risk. These factors
combine to form an ‘allelic spectrum’ (Figure 2). The
allelic spectrum is bounded by ‘common disease/
common variant’ (CDCV) and ‘multiple rare variant’
(MRV) models. The CDCV model postulates the
existence of genetic variants that are relatively
common (perhaps 5–50%) that confer modest risk
(for example, relative risks 1.1–1.5). The MRV model
holds that complex traits result from many different
mutations each of which is individually rare (a few
percent at most and perhaps orders of magnitude less
common) but with very strong effect (for example,
relative risks > 10). These models are not dichoto-
mous and the allelic spectrum is more appropriate.
For example, there are compelling data implicating
eight MODY (maturity onset diabetes of the young)
genes under a MRV model and B15 CDCV variants
for type 2 diabetes. Moreover, genes containing CDCV
could also have as yet undiscovered MRV. Relatively
subtle CDCV alterations establish the importance of a
gene in the pathophysiology of a disease and it is
mechanistically plausible that rare MRV alterations
with strong effects could occur. Framework option ‘f’
could result if the genetic causes of a psychiatric
disorder are exclusively from the left side of the
allelic spectrum. Note that studies of copy number
variation (CNVs) in large samples affords partial
protection under this scenario (for example, 22q11
deletion syndrome is a MRV for schizophrenia with
prevalence of 0.3% and genetic relative risk > 20).5 If
these disorders are caused by a large number of
different mutations, individual genomic sequencing
is likely to be required. This is not now economically
feasible but is anticipated on the 5-year horizon.
Third, GWAS assume a simple additive genetic
model. However, this is only one slice through the
possible parameter space and the true model for any
these psychiatric disorders might not conform to an
additive model. It is possible that some true models
lie in the less detectable parts of the parameter space –
for example, a very large number of contributing loci
all with subtle effects, more complex single locus
effects (for example, dominance or heterosis), inter-
actions (intralocus, gene–gene or gene–environment
interactions) and more intricate models involving
parent-of-origin or epigenetic effects. Given the strik-
ing advances in human genetics in the past decade, it
is prudent to note the possibility of a novel genetic
mechanism. The implication here is that dissecting
the genetic basis of framework option ‘f’ disorders
will be quite difficult and possibly intractable based
on human studies.
Fourth, GWAS currently assess only a subset of
genetic variants. Available GWAS platforms directly
measure SNPs and CNVs and indirectly assess
untyped variants in ‘useful’ linkage disequilibrium
with them. Although the current generation of GWAS
platforms contains B1 million SNPs and provides
‘adequate’ coverage of > 90% of the genome for those
of European or East Asian ancestry, important genetic
Figure 2 Depicts illustrative combinations of disease
mutation frequency and genetic relative risk for a complex
trait. The multiple rare variant (MRV) model is a loose
descriptor for effects at the upper left of the graph and the
common disease/common variant (CDCV) model for those
at the lower right. The term ‘allelic spectrum’ encompasses
both.
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variation could lie in a poorly covered region. More-
over, SNPs and CNVs are only two types of genetic
variation and there are many other types of genetic
variants: important genetic variations that are not
SNPs or CNVs might not be assessed by current
GWAS platforms. This is a technical limitation,
which future generations of GWAS platforms could
remedy.
Fifth, the fundamental pathophysiology may not
map onto the definition of a disorder. Whether this is
or is not the case has been the subject of considerable
debate for over a century and was a driving force for
the repeated revisions of the DSM criteria since 1980.
The limitations of DSM-IV for etiological studies must
be kept in mind: ‘our highest priority has been to
provide a helpful guide to clinical practice’ (page xv)
and ‘these diagnostic criteriay reflect a consensus of
current formulations of evolving knowledge’ (page
xxvii).27 The implication is that different ascertain-
ment strategies or study designs may be needed (for
example, on the basis of a component phenotype
rather than at the disorder level).
Sixth, GWAS assume that the degree of etiological
heterogeneity for each disorder is not prohibitive.
Two extreme positions can be defined: (a) a single
etiological type of disease and (b) as many types of
disease as there are affected individuals. For each of
the five disorders being considered in the PGC, the
former is unlikely and the latter implies that searches
for any type of etiological factor (genetic or otherwise)
will be very difficult. Searches for genetic risk factors
might succeed only if the degree of heterogeneity is
not too awful and if one or a few etiologies
predominate (for example, there might be 10 etiolo-
gical ‘types’ of schizophrenia but one accounts for
half of all cases). Indeed, it is possible that a relatively
modest degree of heterogeneity can make detection of
a subtle association improbable. If it were possible to
index heterogeneity directly (for example, using an
endophenotype),28 this problem could be addressed;
however, there are currently only experimental ways
to index heterogeneity. Indeed, a goal of genetic
studies is to identify genetic markers that can improve
diagnostic classification by indexing heterogeneity.
Careful attention to phenotypic measures (rather than
reliance on diagnoses) could prove to be important for
identifying and replicating susceptibility genes.
Finally, it is unlikely but formally possible that the
genetic epidemiological studies whose results pro-
vide the rationale for GWAS are substantially incor-
rect. Family, adoption and twin studies all make a
variety of assumptions. It is possible that there are
undetected biases or novel etiological factors that led
to overestimations of the importance of genetic
effects.
Conclusions
GWAS has the potential to yield considerable insights
but it is no panacea and may well perform differently
for psychiatric disorders. Even if these psychiatric
GWAS efforts are successful, the outcomes will be
complex. GWAS may help us learn that clinical
syndromes are actually many different things—for
example, proportions of individuals with schizophre-
nia might evidence associations with rare CNVs of
major effect,5,6 with more common genetic variation
in dozens (perhaps hundreds) of genomic regions,
between genetic variation strongly modified by
environmental risk factors, and some proportion
may be genetically indistinguishable from the general
population. Moreover, as fuel to long-standing ‘lum-
per versus splitter’ debates in psychiatric nosology,
empirical data might show that some clinical dis-
orders or identifiable subsets of subjects might over-
lap considerably.
The critical advantage of GWAS is the search of a
‘closed’ hypothesis space. If the large amount of
GWAS data being generated are analyzed within a
strict and coherent framework, it should be possible
to establish hard facts about the fundamental genetic
architecture of a set of important psychiatric dis-
orders—which might include positive evidence of
what these disorders are or exclusionary evidence of
what they are not. Whatever the results, these
historically large efforts should yield hard facts about
ADHD, autism, bipolar disorder, major depressive
disorder and schizophrenia that may help guide the
next era of psychiatric research.
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